Terbinafine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318803

CAS#: 78628-80-5 (HCl)

Description: Terbinafine also known under the trade name Lamisil. It is highly hydrophobic and tends to accumulate in hair, skin, nails, and fatty tissue. It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.

Chemical Structure

Terbinafine HCl
CAS# 78628-80-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 318803
Name: Terbinafine HCl
CAS#: 78628-80-5 (HCl)
Chemical Formula: C21H26ClN
Exact Mass: 291.20
Molecular Weight: 327.900
Elemental Analysis: C, 76.92; H, 7.99; Cl, 10.81; N, 4.27

Price and Availability

Size Price Availability Quantity
100mg USD 190 2 Weeks
200mg USD 350 2 Weeks
500mg USD 550 2 Weeks
1g USD 850 2 Weeks
2g USD 1450 2 Weeks
Bulk inquiry

Related CAS #: 91161-71-6 (free base)   78628-80-5 (HCl)   335276-86-3 (lactate)    

Synonym: BRN 4256376; BRN4256376; BRN-4256376; Terbinafine; Lamisil; Terbinafine HCl; Terbinafine hydrochloride

IUPAC/Chemical Name: (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine hydrochloride


InChi Code: InChI=1S/C21H25N.ClH/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19;/h5-7,9-14H,16-17H2,1-4H3;1H/b9-5+;


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS#91161-71-6 (Terbinafine free base). CAS#78628-80-5 (Terbinafine hydrochloride)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 327.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Dürrbeck A, Nenoff P. [Terbinafine : Relevant drug interactions and their management]. Hautarzt. 2016 Jul 29. [Epub ahead of print] Review. German. PubMed PMID: 27474731.

2: Mayser P. [Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin lesions]. Hautarzt. 2016 Jul 25. [Epub ahead of print] Review. German. PubMed PMID: 27455869.

3: Ma Y, Chen X, Guan S. Terbinafine: novel formulations that potentiate antifungal activities. Drugs Today (Barc). 2015 Mar;51(3):197-208. doi: 10.1358/dot.2015.51.3.2295906. Review. PubMed PMID: 25876563.

4: Yan J, Wang X, Chen S. Systematic review of severe acute liver injury caused by terbinafine. Int J Clin Pharm. 2014 Aug;36(4):679-83. doi: 10.1007/s11096-014-9969-y. Epub 2014 Jul 2. Review. PubMed PMID: 24986266.

5: Kuo S, Sivamani RK. UVB-sensitive solar urticaria possibly associated with terbinafine. Dermatol Online J. 2014 Mar 17;20(3). pii: doj_21753. Review. PubMed PMID: 24656267.

6: Inano S, Kimura M, Iida J, Arima N. Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review. J Infect Chemother. 2013 Dec;19(6):1173-80. doi: 10.1007/s10156-013-0594-9. Epub 2013 Apr 6. Review. PubMed PMID: 23564310.

7: Gupta AK, Drummond-Main C. Meta-analysis of randomized, controlled trials comparing particular doses of griseofulvin and terbinafine for the treatment of tinea capitis. Pediatr Dermatol. 2013 Jan-Feb;30(1):1-6. doi: 10.1111/j.1525-1470.2012.01866.x. Epub 2012 Sep 20. Review. PubMed PMID: 22994156.

8: Sigurgeirsson B, Ghannoum M. Therapeutic potential of TDT 067 (terbinafine in Transfersome): a carrier-based dosage form of terbinafine for onychomycosis. Expert Opin Investig Drugs. 2012 Oct;21(10):1549-62. Epub 2012 Aug 9. Review. PubMed PMID: 22876754.

9: Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):267-72. doi: 10.1111/j.1468-3083.2012.04584.x. Epub 2012 May 28. Review. PubMed PMID: 22632057.

10: Van Duyn Graham L, Elewski BE. Recent updates in oral terbinafine: its use in onychomycosis and tinea capitis in the US. Mycoses. 2011 Nov;54(6):e679-85. doi: 10.1111/j.1439-0507.2011.02038.x. Epub 2011 Jun 12. Review. PubMed PMID: 21668517.

11: Gianni C. Update on antifungal therapy with terbinafine. G Ital Dermatol Venereol. 2010 Jun;145(3):415-24. Review. PubMed PMID: 20461049.

12: Krishnan-Natesan S. Terbinafine: a pharmacological and clinical review. Expert Opin Pharmacother. 2009 Nov;10(16):2723-33. doi: 10.1517/14656560903307462. Review. PubMed PMID: 19874252.

13: Schmid-Wendtner MH, Korting H. [Topical terbinafine. Reduction of duration of therapy for tinea pedis]. Hautarzt. 2008 Dec;59(12):986-91. doi: 10.1007/s00105-008-1552-9. Review. German. PubMed PMID: 18987841.

14: Lorentz K, Booken N, Goerdt S, Goebeler M. Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature. J Dtsch Dermatol Ges. 2008 Oct;6(10):823-7, 823-8. doi: 10.1111/j.1610-0387.2008.06806.x. Epub 2008 Jun 17. Review. English, German. PubMed PMID: 18564209.

15: Schäfer-Korting M, Schoellmann C, Korting HC. Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis. Skin Pharmacol Physiol. 2008;21(4):203-10. doi: 10.1159/000135636. Epub 2008 May 29. Review. PubMed PMID: 18509254.

16: Revankar SG, Nailor MD, Sobel JD. Use of terbinafine in rare and refractory mycoses. Future Microbiol. 2008 Feb;3(1):9-17. doi: 10.2217/17460913.3.1.9. Review. PubMed PMID: 18230029.

17: Kim BS, Jang HS, Jwa SW, Jang BS, Kim MB, Oh CK, Kwon YW, Kwon KS. Generalized pustular psoriasis and hepatic dysfunction associated with oral terbinafine therapy. J Korean Med Sci. 2007 Feb;22(1):167-9. Review. PubMed PMID: 17297275; PubMed Central PMCID: PMC2693560.

18: Gupta AK, Ryder JE, Lynch LE, Tavakkol A. The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. J Drugs Dermatol. 2005 May-Jun;4(3):302-8. Review. PubMed PMID: 15898285.

19: Beltraminelli HS, Lerch M, Arnold A, Bircher AJ, Haeusermann P. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. Br J Dermatol. 2005 Apr;152(4):780-3. Review. PubMed PMID: 15840114.

20: Coskun B, Saral Y, Akpolat N, Ataseven A, Ciçek D. Sporotrichosis successfully treated with terbinafine and potassium iodide: case report and review of the literature. Mycopathologia. 2004 Jul;158(1):53-6. Review. PubMed PMID: 15487321.